Amrinone

Intravenous
Heart failure

Incompatible with glucose-containing solutions and furosemide.

Hypersensitivity.

Obstructive pulmonary or aortic disease, hypertrophic cardiomyopathy; BP and heart rate monitored during drug administration; fluid and electrolyte balance should be maintained; platelet counts and liver function should be monitored; protect amp from light. Pregnancy and lactation.

GI disturbances, nausea, vomiting, thrombocytopaenia, hypotension, chest pain, hypersensitivity, myositis, vasculitis, nail discoloration, Inj site pain, decreased tear production.
Potentially Fatal: Cardiac arrhythmia, hepatotoxicity.

IV/Parenteral: C

May result in severe hypotension. General supportive and symptomatic treatment, including circulatory support, should also be initiated as necessary.

Chemical interaction with precipitation occurs with amrinone and dextrose or furosemide. Thus drug mixing should be avoided.
Potentially Fatal: Concurrent usage with disopyramide may lead to severe hypotension.

Description:
Mechanism of Action: Amrinone is a phosphodiesterase inhibitor which has vasodilating and positive inotropic properties. It causes an increase in cyclic adenosine monophosphate conc leading to greater contractile force in cardiac muscle.
Pharmacokinetics:
Distribution: 10-22% bound to plasma proteins. Half-life after IV admin: 4-6 hr.
Metabolism: Partially metabolised in liver.
Excretion: 40% excreted unchanged.

Store at 15-30°C.

Cardiac Drugs